Quote:

---

20:10: Now, strategy is all about making sure the gospel and in order to make this strategy to work, we can not and really, we must not, continue to pursue every possible indication in tandem. I want to be clear, that in the near term, the company will not be pursuing Covid treatment, either in acute setting or in the long hauler setting. We will not be pursuing GVHD. We will not be pursuing Stroke. We will not be pursuing Multiple Sclerosis. By not pursuing these indications in the near term, it can allow us to focus on the higher value opportunities that we have in NASH and oncology. Going forward, our external persona and corporate brand will evolve to align with our new strategy and I look forward to sharing more about that with you in the future.

---